The installation itself and the apparatus are being validated in anticipation of full operation from the end of 2021; the company said the site is in a position to obtain production qualification batches initiated for consumers to ensure it is in a position to start ad production.
In addition to expanding the production capacity of mobile culture media products, it is an important hub for European markets; offers more local sourcing and savings on shipping costs.
Announcing in July 2019, Fujifilm told us:
“Europe is a major hub for the studies and production of biopharmaceuticals and mobile therapies. Supply chain logistics, threat mitigation and cargo control are key factors for our customers. Producing the product they want closer to their production facilities reduces the threat of source disruption and reduces charges.
“It also allows for fast delivery of the product at a price. Rapid delivery is a fundamental desire for the commercialization of mobile and genetic therapies. “
Despite the chain of origin and the demanding operational situations caused by the COVID-19 pandemic, the company reported that the delivery of an essential apparatus and structure of the new Tilburg facility progressed in 2020.
The facility will have existing Good Manufacturing Practices (cGMP) and will manufacture dry powder media, liquid media, buffers and water for injection (WFI) in accordance with the quality system, uncooked fabrics and expertise used at its facilities in the United States and Japan.
The facility is also in a position to move towards a CO2-neutral state, wind energy for the production process and sustainable technologies such as membrane bioreactors for wastewater treatment, in line with the Fujifilm Group’s sustainability goals until 2030.
More promotional features